Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05100862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05100862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Lead sponsor
BeOne Medicines
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 10, 2022
Completion date
June 30, 2030
Enrollment
799 (actual)
Sites
264

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma, relapsed/refractory follicular lymphoma